Validation of the histone methyltransferase EZH2 as a therapeutic target for various types of human cancer and as a prognostic marker

Masashi Takawa(Kyorin University), Ryuji Hamamoto(RIKEN Center for Advanced Intelligence Project), Kazuhiro Maejima(RIKEN Center for Integrative Medical Sciences), Yukiko Iwai(The University of Tokyo), Yuka Yamane(The University of Tokyo), Gouji Toyokawa(University of Tokyo Hospital), Hyun‐Soo Cho(Korea Research Institute of Bioscience and Biotechnology), Katsunori Takagi(Nagasaki University), Takaaki Kobayashi(University of Kentucky), Masaki Kunizaki(Nagasaki University), Yusuke Nakamura(National Institute of Biomedical Innovation, Health and Nutrition), Takayuki Akasu(Imperial Household Agency), Masanori Sugiyama(University of Toyama), Bruce A.J. Ponder(University of Cambridge), Eijyu Tsuchiya(Kanagawa Prefectural Hospital Organization), Yutaka Atomi(Kyorin University), Ken Masuda(Hiroshima City Asa Citizens Hospital), Helen I. Field(Rockefeller University), Yataro Daigo(The University of Tokyo)
Cancer Science
April 22, 2011
Cited by 191


Related Papers